Ljungström family office co-led AnaCardio AB's €62.5 million Series B, joined Breye Series A

The Ljungström family office co-led AnaCardio AB's €62.5 million Series B alongside Novo Holdings, Family Office Hub reported. Two days earlier the same office joined Breye Therapeutics' €67.5 million Series A as a new investor, according to the report.

AnaCardio, a privately held Swedish clinical-stage company based in Solna, was founded on research from the Karolinska Institutet by Lars H. Lund. Its lead asset, AC01, works through the ghrelin signalling pathway; Family Office Hub describes it as making the heart muscle contract harder without the racing heart, arrhythmia, ischemia and blood-pressure drop that caused earlier contractility drugs to fail.

The Series B fully funds GOAL-HF2, a Phase 2b trial that will enrol about 400 patients at roughly 100 sites in twelve countries. First enrolment is expected in the fourth quarter of 2026, with a Phase 3-ready asset targeted for 2028, according to the report.

In the earlier GOAL-HF1 trial, 58 patients were treated across 14 sites. In the 3 mg group, cardiac output rose 22% from baseline at day 28 and ejection fraction rose 4.8 percentage points, against 1.6 points for placebo; results were presented in May 2026 and published in The Lancet in June, Family Office Hub reports.

Breye Therapeutics ApS, based in Hørsholm in Denmark, is developing orally administered drugs for eye disease. Its lead asset, danegaptide, is described as a first-in-class oral small molecule for non-proliferative diabetic retinopathy, a condition the report says affects roughly 130 million people worldwide and is currently treated, when treated at all, by injection into the eye. Mission BioCapital and Novo Holdings co-led the Series A, which takes danegaptide into a randomised Phase 2 trial starting in 2027.

The two announced rounds total €130 million, but Family Office Hub does not break out Ljungström's individual commitments. Family Office Hub says one of the two investments carried a board seat, but it does not identify which.